Spain's Artax Biopharma raises $10M in funding
Artax Biopharma is a Spanish startup that, after only two years of life, has received an injection of $10M in funding.
Artax is studying drugs that block a protein called NCK to stop lymphocytes from attacking healthy tissues.
This young startup has a staff of only 4 employees but this has not prevented them from attracting the attention of foreign investors. The round has been led by Henri Termeer, CEO of Genzyme and the European fund Advent Life Sciences and other individual investors have also participated.
Artax Biopharma has offices in Valencia and Cambridge.
PharmaMar consolidates its internalisation
PharmaMar announced this week that its partner in Japan, Taiho Pharmaceutical, has received approval from the Japanese Ministry of Health to market its drug Yondelis for the treatment of patients with soft tissue sarcoma.
In mid-September, PharmaMar opened a subsidiary in London, strengthening its business in Europe after Italy, Germany, France, Switzerland and Spain, where it is headquartered.
PharmaMar also plans to enter the US market at the end of this year and to go public in the US by mid-2016.
"PharmaMar, which started out as Zeltia's oncology division, specialising in the development of drugs with molecules extracted from the seabed, has been growing and becoming the jewel in Zeltia's crown. So much so that in June 2015 the merger of Zeltia with the oncology subsidiary was approved and Pharmamar took the lead of the group. What started out as a risky investment with more hope than ambition has become a success, and with only one drug on the market, the anti-tumour drug Yondelis, PharmaMar contributes 90 % of the company's value", says Diego Gutierrez of Abra-invest
Mind The Byte raises round of funding
La barcelonesa Mind the Byte specialising in services for computational drug design, has presented at the PCB a campaign of crowdfunding 100,000 managed by Crowdcube with the aim of boosting the international marketing of its services and products. cloud for computational drug design in SaaS mode.
This transaction is the company's second capital increase in less than a year, as at the end of 2014 it closed a €200,000 round led by InKemia.
Mind the Byte has just opened a subsidiary in the Copenhagen Bio Science Park (COBIS), as the first step in a process of international expansion that the company will start-up has just started with the help of ACCIÓ.
If you want to get both public and private funding, please contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Call us at +34 946424142 or fill out the contact form
Other posts that may interest you
Biotech investment news September 2015: CaixaIpulse, Sanifit and Centauri